Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine : vimarsana.com

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Matt Crenson , Ian Karp , John Leonard , Lina Li , European Medicines Agency , European Commission , Exchange Commission , Clinical Immunology Hybrid Congress , Corporate Communications , Regulatory Agency , Nasdaq , Intellia Therapeutics Inc , Drug Administration , European Academy Of Allergy , Clinical Program , Therapeutics Announces Publication , Positive Interim Phase , Hereditary Angioedema , New England Journal , Intellia President , Chief Executive Officer , Clinical Immunology Hybrid , Orphan Drug , Innovation Passport , Priority Medicines , Orphan Drug Designation , Intellia Therapeutics , Private Securities Litigation Reform Act , Vice President , Investor Relations ,